Westmount Partners LLC Sells 7,506 Shares of Illumina, Inc. $ILMN

Westmount Partners LLC lessened its holdings in Illumina, Inc. (NASDAQ:ILMN) by 15.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 40,103 shares of the life sciences company’s stock after selling 7,506 shares during the quarter. Illumina accounts for approximately 1.3% of Westmount Partners LLC’s investment portfolio, making the stock its 16th biggest position. Westmount Partners LLC’s holdings in Illumina were worth $5,260,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Board of the Pension Protection Fund bought a new position in Illumina in the fourth quarter valued at about $26,000. Quent Capital LLC bought a new position in shares of Illumina in the third quarter worth about $29,000. Quarry LP acquired a new stake in shares of Illumina in the 3rd quarter valued at approximately $32,000. Aster Capital Management DIFC Ltd bought a new stake in shares of Illumina during the 3rd quarter valued at approximately $33,000. Finally, Strategic Advocates LLC bought a new stake in shares of Illumina during the 3rd quarter valued at approximately $44,000. Institutional investors own 89.42% of the company’s stock.

Insider Buying and Selling

In other Illumina news, SVP Patricia Leckman sold 2,370 shares of the company’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total value of $275,346.60. Following the sale, the senior vice president owned 16,321 shares in the company, valued at approximately $1,896,173.78. The trade was a 12.68% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.17% of the company’s stock.

Analysts Set New Price Targets

ILMN has been the subject of several research reports. Evercore set a $150.00 price objective on shares of Illumina in a research note on Friday, February 6th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Illumina in a research note on Monday, December 29th. Canaccord Genuity Group boosted their price objective on Illumina from $130.00 to $150.00 and gave the stock a “hold” rating in a research report on Monday, January 26th. TD Cowen reaffirmed a “hold” rating on shares of Illumina in a report on Wednesday, January 7th. Finally, Barclays increased their target price on Illumina from $100.00 to $110.00 and gave the company an “underweight” rating in a research report on Monday, December 15th. Six research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $129.69.

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $123.26 on Wednesday. The firm has a market cap of $18.85 billion, a PE ratio of 22.62, a price-to-earnings-growth ratio of 2.31 and a beta of 1.45. The firm’s fifty day moving average is $127.91 and its 200-day moving average is $122.22. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.72 and a current ratio of 2.08. Illumina, Inc. has a 52 week low of $68.70 and a 52 week high of $155.53.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, February 5th. The life sciences company reported $1.35 earnings per share for the quarter, beating analysts’ consensus estimates of $1.26 by $0.09. The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.10 billion. Illumina had a return on equity of 31.04% and a net margin of 19.57%.Illumina’s quarterly revenue was up 5.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.95 earnings per share. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Sell-side analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.